/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. We have historically advanced early-stage product candidates and we are pursuing new product candidates and platforms to build a product pipeline based on our deep understanding of immunotherapies.
$0.09
+$0.00 (+0.00%)
Price from 3 days ago
Negative free cash flow of -$111K. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$687K
▲ +25.4% YoY
Op. Margin
—
ROIC
-32.35%
▲ +17.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$54K
▲ +53.8% YoY
Op. Cash Flow (TTM)
-$54K
▲ +53.8% YoY
Net Debt
$2M
Cash & Equiv.
$26.00
Continue Research
SourceComputed from the 10-Q filed 14 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 15 Aug 2026. How this is calculated.
Price from market data, last close as of 17 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.